The company projects plozasiran to generate $2 billion to $3 billion annually in the SHTG market alone, with Phase III studies (SHASTA-3, SHASTA-4, and MUIR 3) expected to complete enrollment this ...
During the recent period, Arrowhead (ARWR) signed and closed a potentially transformational licensing and collaboration agreement with Sarepta ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback